http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Scott Baker ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Genetic evidence of illegal trade in protected whales links Japan with the US and South Korea
Baker, C. Scott,Steel, Debbie,Choi, Yeyong,Lee, Hang,Kim, Kyung Seok,Choi, Sung Kyoung,Ma, Yong-Un,Hambleton, Charles,Psihoyos, Louie,Brownell, R. L.,Funahashi, Naoko The Royal Society 2010 Biology letters Vol.6 No.5
<P>We report on genetic identification of ‘whale meat’ purchased in sushi restaurants in Los Angeles, CA (USA) in October 2009 and in Seoul, South Korea in June and September 2009. Phylogenetic analyses of mtDNA cytochrome <I>b</I> sequences confirmed that the products included three species of whale currently killed in the controversial scientific whaling programme of Japan, but which are protected from international trade: the fin, sei and Antarctic minke. The DNA profile of the fin whale sold in Seoul established a match to products purchased previously in Japan in September 2007, confirming unauthorized trade between these two countries. Following species identification, these products were handed over to the appropriate national or local authorities for further investigation. The illegal trade of products from protected species of whales, presumably taken under a national permit for scientific research, is a timely reminder of the need for independent, transparent and robust monitoring of any future whaling.</P>
-
( Andrew Huynh ),( Scott Baker ),( Andrew Stewardson ),( Douglas Johnson ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Denosumab, a humanised monoclonal antibody against receptor activator of nuclear factor kappa beta ligand (RANKL), reduces bone turnover via inhibition of osteoclasts and osteoclastogenesis and is used in the management of osteoporosis and metastatic bone disease. While hypocalcaemia complicating denosumab treatment has been reported, the real world incidence, clinical and biochemical risk factors are not fully elucidated. This study aims to investigate the incidence of denosumab-associated hypocalcaemia (DAH) and identify relevant clinical and investigation features. Methods: We performed a retrospective observational audit of patients administered denosumab (60mg/120mg) over a 12 month period at a tertiary hospital in Australia. Data collected: denosumab dosage and indication, 25-hydroxyvitamin D concentration, parathyroid hormone, estimated glomerular filtration rate (eGFR), nadir and duration of hypocalcaemia (albumin adjusted serum calcium concentration <2.15 mmol/L or ionised calcium <1.13 mmol/L upto 6 months post denosumab administration), calcium and colecalciferol pre- and post-administration of denosumab. The primary outcome was the incidence proportion of DAH. Results: Of 161 patients administered denosumab (106 osteoporosis, 55 bone metastases), 20 patients (12.4%, mean age 78.5 years, 11 male, 11 osteoporosis, 9 bone metastases) developed hypocalcaemia. Median calcium nadir was 2.06 mmol/L (interquartile range (IQR) 1.81-2.11), with the median time to diagnosis 24.50 days (IQR 9.25-41.25). One patient required intravenous calcium gluconate treatment. 75% of affected patients had a 25-hydroxyvitamin D concentration >50nmol/L and 90% of affected patients were on calcium or colecalciferol supplementation. DAH was associated with sex (27% males versus 8% females, p=0.004), but not age (8% under 60 years versus 13% aged 60 or more, p=0.74) or indication (16% with bone metastases versus 10% with osteoporosis, p=0.32). Conclusions: Denosumab-associated hypocalcaemia occurred in over 12% of patients in this population, despite wide use of appropriate calcium and colecalciferol supplementation.
-
Alyna Turner,John J. McGrath,Olivia M. Dean,Seetal Dodd,Andrea Baker,Susan M. Cotton,James G. Scott,Bianca E. Kavanagh,Melanie M. Ashton,Adam J. Walker,Ellie Brown,MIchael Berk 대한정신약물학회 2019 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.17 No.2
Objective: Garcinia mangostana Linn., commonly known as mangosteen, is a tropical fruit with a thick pericarp rind containing bioactive compounds that may be beneficial as an adjunctive treatment for schizophrenia. The biological underpinnings of schizophrenia are believed to involve altered neurotransmission, inflammation, redox systems, mitochondrial dysfunction, and neurogenesis. Mangosteen pericarp contains xanthones which may target these biological pathways and improve symptoms; this is supported by preclinical evidence. Here we outline the protocol for a double- blind randomized placebo-controlled trial evaluating the efficacy of adjunctive mangosteen pericarp (1,000 mg/day), compared to placebo, in the treatment of schizophrenia. Methods: We aim to recruit 150 participants across two sites (Geelong and Brisbane). Participants diagnosed with schizophrenia or schizoaffective disorder will be randomized to receive 24 weeks of either adjunctive 1,000 mg/day of mangosteen pericarp or matched placebo, in addition to their usual treatment. The primary outcome measure is mean change in the Positive and Negative Symptom Scale (total score) over the 24 weeks. Secondary outcomes include positive and negative symptoms, general psychopathology, clinical global severity and improvement, depressive symptoms, life satisfaction, functioning, participants reported overall improvement, substance use, cognition, safety and biological data. A 4-week post treatment interview at week 28 will explore post-discontinuations effects. Results: Ethical and governance approvals were gained and the trial commenced. Conclusion: A positive finding in this study has the potential to provide a new adjunctive treatment option for people with schizophrenia and schizoaffective disorder. It may also lead to a greater understanding of the pathophysiology of the disorder.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
